Zobrazeno 1 - 10
of 49
pro vyhledávání: '"François-Clement Bidard"'
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Overall sequencing CONSORT diagram. Flow diagram of study patients and analyzed biospecimens processed through and selected for central sequencing using MSK-IMPACT and Guardant360. cfDNA, cell-free DNA; FFPE, formalin-fixed paraffin-embedded; MSK-IMP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fadd31b50eb28b778540b40ef3547376
https://doi.org/10.1158/2159-8290.22535392.v1
https://doi.org/10.1158/2159-8290.22535392.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
HER2 mutations define a subset of metastatic breast cancers with a unique mechanism of oncogenic addiction to HER2 signaling. We explored activity of the irreversible pan-HER kinase inhibitor neratinib, alone or with fulvestrant, in 81 patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::df3c52be345cb95e67d14e31497f606f
https://doi.org/10.1158/2159-8290.c.6547849.v1
https://doi.org/10.1158/2159-8290.c.6547849.v1
Autor:
David M. Hyman, Funda Meric-Bernstam, David B. Solit, Barry S. Taylor, José Baselga, Richard Bryce, Alshad S. Lalani, Melanie Dujka, Lisa D. Eli, Feng Xu, Grace Mann, Maurizio Scaltriti, Yanyan Cai, Aliaksandra Samoila, Myra Melcer, S. Duygu Selcuklu, Catherine Zimel, Elena I. Gavrila, Komal Jhaveri, Sarat Chandarlapaty, Gary A. Ulaner, Rebecca J. Nagy, Richard B. Lanman, Alexander N. Gorelick, François-Clement Bidard, Andrés Cervantes, Xavier Gonzàlez-Farré, Lee S. Schwartzberg, Joohyuk Sohn, Valentina Boni, Victor Moreno, Monica Arnedos, Morten Mau-Sørensen, Iben Spanggaard, Adam M. Brufksy, Macarena I. de la Fuente, Carlos L. Arteaga, Ingrid A. Mayer, Dejan Juric, Geoffrey I. Shapiro, Janice Lu, Sherene Loi, Cristina Saura, Alison M. Schram, Helen H. Won, Sarina A. Piha-Paul, Lillian M. Smyth
Supplementary data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9a66139c86c7fc9c7963ce2aff13cc
https://doi.org/10.1158/2159-8290.22535398
https://doi.org/10.1158/2159-8290.22535398
Autor:
Anthony Lucci, Klaus Pantel, Sara Y. Brucker, Peter A. Fasching, Thomas W.P. Friedl, François-Clement Bidard, Marco R. de Groot, Carolyn Hall, Tanja Fehm, Florin-Andrei Taran, Jean-Yves Pierga, Leon W.M.M. Terstappen, Brigitte Rack, Wolfgang J. Janni
supplemental figure legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05562f1b88cf1e7921ff76ea3a274441
https://doi.org/10.1158/1078-0432.22459256
https://doi.org/10.1158/1078-0432.22459256
Autor:
Anthony Lucci, Klaus Pantel, Sara Y. Brucker, Peter A. Fasching, Thomas W.P. Friedl, François-Clement Bidard, Marco R. de Groot, Carolyn Hall, Tanja Fehm, Florin-Andrei Taran, Jean-Yves Pierga, Leon W.M.M. Terstappen, Brigitte Rack, Wolfgang J. Janni
Figure S1. Flow chart of the data selection process for a pooled analysis of the prognostic relevance of circulating tumor cells in early breast cancer. Patients were ineligible if no valid data on CTC presence at the time of primary diagnosis as ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91c74f8b794ccb10191833472bae95c4
https://doi.org/10.1158/1078-0432.22459274.v1
https://doi.org/10.1158/1078-0432.22459274.v1
Autor:
Anthony Lucci, Klaus Pantel, Sara Y. Brucker, Peter A. Fasching, Thomas W.P. Friedl, François-Clement Bidard, Marco R. de Groot, Carolyn Hall, Tanja Fehm, Florin-Andrei Taran, Jean-Yves Pierga, Leon W.M.M. Terstappen, Brigitte Rack, Wolfgang J. Janni
Purpose: Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTC) in the peripheral blood of patients with metastatic breast cancer, less evidence is available for the prognostic relevance of CTCs at the time
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4162a93fe63e1257cad59434c6890b5
https://doi.org/10.1158/1078-0432.c.6524183.v1
https://doi.org/10.1158/1078-0432.c.6524183.v1
Autor:
Anthony Lucci, Klaus Pantel, Sara Y. Brucker, Peter A. Fasching, Thomas W.P. Friedl, François-Clement Bidard, Marco R. de Groot, Carolyn Hall, Tanja Fehm, Florin-Andrei Taran, Jean-Yves Pierga, Leon W.M.M. Terstappen, Brigitte Rack, Wolfgang J. Janni
Table S1. Patients and study variables according to study center for the pooled analysis of circulating tumor cells in early breast cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b255db61f4471fa1496e101a93e90b7
https://doi.org/10.1158/1078-0432.22459259
https://doi.org/10.1158/1078-0432.22459259
Autor:
Komal Jhaveri, Haeseong Park, James Waisman, Jonathan W Goldman, Angel Guerrero-Zotano, Valentina Boni, Barbara Haley, Ingrid A Mayer, Adam Brufsky, Eddy S Yang, José A García-Sáenz, François-Clement Bidard, John Crown, Bo Zhang, Aimee Frazier, Irmina Diala, Lisa D Eli, Brian Barnett, Hans Wildiers
Publikováno v:
Cancer Research. 82:GS4-10
Background: HER2 mutations are oncogenic drivers in a subset of metastatic breast cancers (MBC). Neratinib (N) is an oral, irreversible pan-HER tyrosine kinase inhibitor with preclinical and clinical activity against HER2 mutations. Genomic analyses
Autor:
Sara A. Hurvitz, François-Clement Bidard, Wei Li, Xichun Hu, Sonia Pernas, Joseph Thaddeus Beck, Mario Campone, Kevin Punie, Michelle Miller, Mathilde Kaper, Yu Han, Farhat Ghaznawi, Guy Jerusalem
Publikováno v:
Cancer Research. 83:4926-4926
Introduction: Current standard first-line (1L) treatment (tx) for patients (pts) with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (ABC) includes taxanes plus trastuzumab (T) and pertuzumab (P). Mutations (mut) in p
Autor:
Frédérique, Berger, Margaux, Marce, Suzette, Delaloge, Anne-Claire, Hardy-Bessard, Thomas, Bachelot, Ivan, Bièche, Anne, Pradines, Thibault, De La Motte Rouge, Jean-Luc, Canon, Fabrice, André, Laurent, Arnould, Florian, Clatot, Jérôme, Lemonnier, Sandrine, Marques, François-Clement, Bidard, S, Marques
Publikováno v:
BMJ open. 12(3)
IntroductionThe combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howeve